Literature DB >> 22430638

CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients.

N Hosen1, Y Matsuoka, S Kishida, J Nakata, Y Mizutani, K Hasegawa, A Mugitani, H Ichihara, Y Aoyama, S Nishida, A Tsuboi, F Fujiki, N Tatsumi, H Nakajima, M Hino, T Kimura, K Yata, M Abe, Y Oka, Y Oji, A Kumanogoh, H Sugiyama.   

Abstract

Clonogenic multiple myeloma (MM) cells reportedly lacked expression of plasma cell marker CD138. It was also shown that CD19(+) clonotypic B cells can serve as MM progenitor cells in some patients. However, it is unclear whether CD138-negative clonogenic MM plasma cells are identical to clonotypic CD19(+) B cells. We found that in vitro MM colony-forming cells were enriched in CD138(-)CD19(-)CD38(++) plasma cells, while CD19(+) B cells never formed MM colonies in 16 samples examined in this study. We next used the SCID-rab model, which enables engraftment of human MM in vivo. CD138(-)CD19(-)CD38(++) plasma cells engrafted in this model rapidly propagated MM in 3 out of 9 cases, while no engraftment of CD19(+) B cells was detected. In 4 out of 9 cases, CD138(+) plasma cells propagated MM, although more slowly than CD138(-) cells. Finally, we transplanted CD19(+) B cells from 13 MM patients into NOD/SCID IL2Rγc(-/-) mice, but MM did not develop. These results suggest that at least in some MM patients CD138-negative clonogenic cells are plasma cells rather than B cells, and that MM plasma cells including CD138(-) and CD138(+) cells have the potential to propagate MM clones in vivo in the absence of CD19(+) B cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22430638     DOI: 10.1038/leu.2012.80

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  29 in total

1.  Reply to “Response to “CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype”. Haematologica 2012;97(7):1110-1114.

Authors:  Teresa Paíno; Bruno Paiva; Jesús San Miguel
Journal:  Haematologica       Date:  2013-01       Impact factor: 9.941

Review 2.  Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma.

Authors:  Yusuke Furukawa; Jiro Kikuchi
Journal:  Int J Hematol       Date:  2016-07-13       Impact factor: 2.490

Review 3.  Identify multiple myeloma stem cells: Utopia?

Authors:  Ilaria Saltarella; Aurelia Lamanuzzi; Antonia Reale; Angelo Vacca; Roberto Ria
Journal:  World J Stem Cells       Date:  2015-01-26       Impact factor: 5.326

4.  CD138 Negative Plasma Cells in Relapsed CNS Multiple Myeloma.

Authors:  Neha Singh; Jatin S Gandhi; Narendra Agrawal; Ajit Panaych; Narender Tejwani; Anurag Mehta
Journal:  Indian J Hematol Blood Transfus       Date:  2017-02-07       Impact factor: 0.900

5.  CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway.

Authors:  Dan Wu; Xinyi Guo; Jing Su; Ruoying Chen; Dmitriy Berenzon; Martin Guthold; Keith Bonin; Weiling Zhao; Xiaobo Zhou
Journal:  Biochim Biophys Acta       Date:  2014-11-21

6.  Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma.

Authors:  M Hiasa; J Teramachi; A Oda; R Amachi; T Harada; S Nakamura; H Miki; S Fujii; K Kagawa; K Watanabe; I Endo; Y Kuroda; T Yoneda; D Tsuji; M Nakao; E Tanaka; K Hamada; S Sano; K Itoh; T Matsumoto; M Abe
Journal:  Leukemia       Date:  2014-05-02       Impact factor: 11.528

7.  Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential.

Authors:  T Paíno; B Paiva; J M Sayagués; I Mota; T Carvalheiro; L A Corchete; I Aires-Mejía; J J Pérez; M L Sanchez; P Barcena; E M Ocio; L San-Segundo; M E Sarasquete; R García-Sanz; M-B Vidriales; A Oriol; M-T Hernández; M-A Echeveste; A Paiva; J Blade; J-J Lahuerta; A Orfao; M-V Mateos; N C Gutiérrez; J F San-Miguel
Journal:  Leukemia       Date:  2014-11-12       Impact factor: 11.528

8.  Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

Authors:  Alfred L Garfall; Edward A Stadtmauer; Wei-Ting Hwang; Simon F Lacey; Jan Joseph Melenhorst; Maria Krevvata; Martin P Carroll; William H Matsui; Qiuju Wang; Madhav V Dhodapkar; Kavita Dhodapkar; Rituparna Das; Dan T Vogl; Brendan M Weiss; Adam D Cohen; Patricia A Mangan; Emily C Ayers; Selene Nunez-Cruz; Irina Kulikovskaya; Megan M Davis; Anne Lamontagne; Karen Dengel; Naseem Ds Kerr; Regina M Young; Donald L Siegel; Bruce L Levine; Michael C Milone; Marcela V Maus; Carl H June
Journal:  JCI Insight       Date:  2018-04-19

Review 9.  Multiple myeloma-initiating cells.

Authors:  Naoki Hosen
Journal:  Int J Hematol       Date:  2013-02-19       Impact factor: 2.490

10.  HIF-1α and rapamycin act as gerosuppressant in multiple myeloma cells upon genotoxic stress.

Authors:  Clémence Coudre; Julien Alani; William Ritchie; Véronique Marsaud; Brigitte Sola; Julie Cahu
Journal:  Cell Cycle       Date:  2016-06-24       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.